Program Description
Atherosclerotic cardiovascular disease accounts for the majority of cardiovascular-related deaths worldwide. Elevated low-density lipoprotein cholesterol (LDL-C) remains one of its most modifiable drivers. Updated American College of Cardiology/American Heart Association guidance lowers LDL-C targets for at-risk patients. Yet many patients do not reach LDL-C goals on statin therapy alone, and nonstatin options available in injectable and oral forms offer guideline-supported LDL-C lowering. Still, adoption lags across health systems, slowed by inconsistent documentation, restrictive prior authorization criteria, and formulary pathways that trail behind evidence. Pharmacists in integrated delivery networks are positioned to provide leadership across pharmacy and therapeutics committees, formulary, utilization management, and clinical program decisions. Aligning systemwide policies with current evidence can help clinical specialists support high-risk patients in receiving guideline-concordant therapy that lowers their risk of cardiovascular events.
Target audience: Health System Pharmacists and Managed Care Pharmacists
Type of activity: Application
Release date: November 17, 2026
Expiration date: January 16, 2027
Time to complete activity: 1.5 hours
Learner level: Foundational, Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, pharmacists will be able to:
- Explain the clinical and economic burden of atherosclerotic cardiovascular disease
- Apply risk-stratification models and lipid biomarker evaluation to patients who require early cardiovascular intervention
- Analyze updated clinical guideline recommendations and the evolving evidence base for established and emerging nonstatin lipid-lowering therapies
- Explore population-health strategies that identify and support high-risk patients across the care continuum, improving access to nonstatin therapies and advancing value-based care through coordinated, timely treatment
Ty Gluckman
Steven Kheloussi, PharmD, MBA, FAMCP
Principal Consultant
Kheloussi Consulting, LLC
Adjunct Professor of Pharmacy Practice
Wilkes University Nesbitt School of Pharmacy
Wilkes-Barre, PA
Accreditation Information
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This application-based activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number [UAN pending]. The activity is available for CE credit through January 16, 2027.
Obtaining Credit
All participants who attended the live virtual broadcast need to log on to their Pharmacy Times Continuing Education™ account on www.pharmacytimes.org to complete an online evaluation form and request their credit. Instructions on receiving credit will be provided the day of the event.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Steven Kheloussi, PharmD, MBA, FAMCP, has no relevant financial relationships with ineligible companies to disclose.
The staff of Pharmacy Times Continuing Education™ have no relevant financial relationships with ineligible companies.
At least 1 anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms